Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)
15.70
0.00 (0.00%)
Apr 3, 2025, 4:08 PM HKT
HKG:2196 Revenue
In the year 2024, Shanghai Fosun Pharmaceutical (Group) had annual revenue of 41.07B CNY, down -0.80%. Shanghai Fosun Pharmaceutical (Group) had revenue of 10.16B in the quarter ending December 31, 2024, a decrease of -5.09%.
Revenue
41.07B CNY
Revenue Growth
-0.80%
P/S Ratio
n/a
Revenue / Employee
1.02M CNY
Employees
40,370
Market Cap
66.12B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.07B | -332.34M | -0.80% |
Dec 31, 2023 | 41.40B | -2.55B | -5.81% |
Dec 31, 2022 | 43.95B | 4.94B | 12.66% |
Dec 31, 2021 | 39.01B | 8.70B | 28.72% |
Dec 31, 2020 | 30.31B | 1.72B | 6.02% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Alibaba Health Information Technology | 31.39B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
Shanghai Fosun Pharmaceutical (Group) News
- 7 days ago - Shanghai Fosun Pharmaceutical reports FY results - Seeking Alpha
- 1 year ago - Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse - Reuters
- 2 years ago - Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech - Forbes
- 3 years ago - Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal - Seeking Alpha
- 4 years ago - Pandemic Accelerates China's Drive Into mRNA Treatments - Seeking Alpha
- 4 years ago - Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse - Seeking Alpha
- 4 years ago - Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal - Seeking Alpha
- 4 years ago - Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations - CNBC